Insilico's AI-designed TEAD inhibitor earns FDA Fast Track f

Insilico Medicine's ISM6331, a small molecule inhibitor designed by its AI platform, has received FDA Fast Track Designation for treating advanced mesothelioma. This marks the first time an AI-designed, non-covalent pan-TEAD inhibitor has reached this regulatory milestone, with initial clinical data expected in October 2026.

This Wire brief sits within Fusion42's coverage of Drug Discovery. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.